Opdivo (Nivolumab) is one of the most advanced and well-known immunotherapy drugs for cancer treatment worldwide. It belongs to the PD-1 inhibitors class and has significantly improved outcomes for many cancer patients.
What is Opdivo?
Opdivo works by boosting the immune system to recognize and attack cancer cells. It blocks the PD-1 protein that cancer cells use to escape immune detection.
Indications for Opdivo
It is prescribed for various cancers, including:
-
Non-small cell lung cancer (NSCLC).
-
Advanced melanoma.
-
Head and neck cancers.
-
Liver cancer.
-
Kidney and bladder cancers.
Dosage and Administration
-
Administered via intravenous infusion in a hospital or oncology center.
-
Usually every 2 or 4 weeks.
-
Infusion takes about 30 minutes.
Side Effects
-
Fatigue.
-
Loss of appetite and weight loss.
-
Cough or shortness of breath.
-
Skin rash and itching.
-
Liver or lung inflammation.
-
Endocrine gland disorders.
Contraindications
-
Severe allergy to drug components.
-
Patients with organ transplants.
-
Those on strong immunosuppressants.
Manufacturer
Opdivo is produced by Bristol-Myers Squibb (BMS), a leading global pharmaceutical company.
Opdivo in Egypt with Macrocare
In Egypt, Opdivo is available in selected oncology centers, but due to its high cost, careful coordination is required. Macrocare helps by:
-
Coordinating treatment plans with Opdivo.
-
Providing treatment options in Egypt and abroad.
-
Offering step-by-step patient support.
Conclusion
Opdivo (Nivolumab) is a groundbreaking immunotherapy drug that offers real hope for cancer patients. Despite its high cost, its effectiveness makes it one of the most sought-after treatments. With Macrocare, you gain access to world-class treatment protocols and comprehensive care.